España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Davis Fundamental ETF Trust Davis Select U.S. Equity ETF
DUSA
BATS
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$42.36
0.43
1.03%
At close: -
Get Report
Comment
Overview
News
Holdings
Dividends
Short Interest
Latest news for Davis Fundamental ETF Trust Davis Select U.S. Equity ETF (BATS:DUSA)
Davis Fundamental ETF Trust Davis Select U.S. Equity ETF (BATS: DUSA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Sunday, January 19, 2020
4 ETFs For Alphabet's Ascent Into The Four Comma Club
ETF Professor
Wednesday, April 12, 2017
A Solid Start For A New Active ETF
Benzinga
Monday, December 17, 2012
C.K. Cooper & Company Reiterates Buy on DUSA Pharmaceuticals, Inc., Maintains $9.50 PT
Benzinga
Wednesday, December 05, 2012
Caraco, DUSA Pharma Announce Early Termination of Hart-Scott-Rodino Waiting Period for Tender Offer
Benzinga
Thursday, November 08, 2012
Shares of DUSA Pharma Up 38+% Following $8/Sh...
Benzinga
Thursday, September 13, 2012
DUSA Pharma Says Positive Results in Phase 2 Actinic
Benzinga
Thursday, August 02, 2012
Dusa Pharmaceuticals Reports Q2 EPS $0.06 vs $0.06 Est; Revenues $11.7M vs $11.85M Est
Benzinga
Dusa Pharmaceuticals Reports Q2 EPS $0.06 vs $0.06 Est; Revenues $11.7M vs $11.85M Est
Benzinga
Tuesday, May 08, 2012
Dusa Pharmaceuticals Reports Q1 EPS $0.08 vs $0.07 Est; Revenues $13.4M vs $12.92M Est
Benzinga
Tuesday, April 24, 2012
DUSA Pharmaceuticals Completes Enrollment in Phase 2 Studies of Levulan Kerastick Photodynamic Therapy
Benzinga
Tuesday, March 06, 2012
UPDATE: C.K. Cooper Initiates Coverage on DUSA Pharmaceuticals
Benzinga
CK Cooper Initiates Coverage on Dusa Pharmace...
Benzinga
Tuesday, January 31, 2012
Potential Trades This Week: Looking For Consolidation
Benzinga
Monday, January 30, 2012
Weekly Traders Homework: Frustrated Bears
Benzinga
Monday, June 27, 2011
DUSA Pharmaceuticals Added to Russell 3000 Index
Benzinga
Friday, May 06, 2011
Preventing the Most Common Form of Cancer (DUSA)
Benzinga
Preventing the Most Common Form of Cancer (DUSA)
Benzinga
Thursday, May 05, 2011
Top Percentage Gainers and Losers as of 2pm 04/05/11 (KNDL, DUSA, ROCK, PPO, BDCO, MW, FONR, LEAP, TBL, SCEI, SMSI, SVNT, GLBL, DEER, UDRL, ARO)
Benzinga
Top Percentage Gainers and Losers as of 12pm 04/05/11 (KNDL, PPO, DUSA, ROCK, SHS, TBL, SMSI, ARO, SCEI, SVNT)
Benzinga
Friday, March 25, 2011
DUSA Pharmaceuticals Up Almost 8% (DUSA)
Benzinga
Monday, March 14, 2011
(DUSA) Keep an Eye on (DUSA) Above $4.42 great breakout on charts
Benzinga
Thursday, March 03, 2011
NASDAQ Stocks Hitting 52-Week Highs (GTEC, SIMO, ERIC, DUSA)
Benzinga
Morning Market Movers (GTEC, ASGR, LSBK, DUSA)
Benzinga
Dusa Pharmaceuticals Reports Q4 EPS of $0.12
Benzinga